rak, based on what I've seen from the FDA in past rejections, if they finally let us into the promised land, people will use it, cuz it will work wonderfully. Of course, I'm assuming that it it can be prescribed for people with Type 1 and Type 2 - can't imagine there would be a label restriction against use by Type 2's, am I wrong on this assumption? The market is so, so large, it will only take capturing a small percentage of it initially to make a lot of money. And even with a modest share of the market in the future, that's still big money.

I hope that when the results are made public, and let's say the company calls the results a success, that there are those on this board who can analyze OBJECTIVELY just how good those results are, especially if the share price action is saying, essentially, "you passed the test, but hardly with flying colors."